AstraZeneca (AZN) vs Novartis (NOVN)
AstraZeneca (AZN) and Novartis (NOVN) side by side: both in Healthcare, listed on London Stock Exchange and SIX Swiss Exchange.
| Field | AstraZeneca | Novartis |
|---|---|---|
| Legal name | AstraZeneca PLC | Novartis AG |
| Ticker | AZN | NOVN |
| Exchange | London Stock Exchange XLON | SIX Swiss Exchange XSWX |
| Jurisdiction | United Kingdom | Switzerland |
| Sector | Healthcare | Healthcare |
| Industry | Pharmaceuticals | Pharmaceuticals |
| Market cap ≈ | $230bn | $230bn |
| Founded | 1999 | 1996 |
| Reporting currency | GBP | CHF |
| LEI | PY6ZZQWO2IZFZC3IOL08 | 5493007HIVTX6SY6XD66 |
| ISIN | GB0009895292 | CH0012005267 |
| FIGI | BBG001SCNW31 | BBG001SD31N7 |
| Index membership | FTSE 100 | — |
| Held by (covered funds) | — | — |
AstraZeneca
Anglo-Swedish pharmaceutical company formed by the 1999 merger of Astra AB and Zeneca Group, with major franchises in oncology, cardiovascular and rare diseases. One of the largest companies on the London Stock Exchange.
Novartis
Basel-based pharmaceutical company created by the 1996 merger of Ciba-Geigy and Sandoz, now a pure-play innovative-medicines business after spinning off Alcon and Sandoz. Key franchises include cardiovascular, oncology and immunology drugs.
Approximate reference values (seed-0.6 · 2026-08-29) — not real-time, not investment advice. Both sides as data: /api/v1/companies/astrazeneca · /api/v1/companies/novartis